Efficacy News and Research

RSS

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

Researchers disagree over ethics of HIV treatment clinical trial in Africa, Nature reports

Nature reports how "a potential breakthrough in the quest to prevent HIV and AIDS has collided with sensitivities about testing expensive drugs in poor parts of the world."

18 Jan 2013

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company researching a new class of glycobiology-based therapies for a broad range of diseases, today announced that it has completed enrolling patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate.

18 Jan 2013

SyNAPSe® Trial by BHR Pharma deemed to have no safety issues according to DSMB

BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.

17 Jan 2013

New menu of 61 genetically engineered E. coli strains may improve efficacy of vaccines

Researchers at The University of Texas at Austin have developed a menu of 61 new strains of genetically engineered bacteria that may improve the efficacy of vaccines for diseases such as flu, pertussis, cholera and HPV.

17 Jan 2013

QrxPharma to resubmit MOXDUO NDA with FDA

QRxPharma Limited announced today that the steps necessary for approval of immediate release MOXDUO have been clarified with the United States Food and Drug Administration (FDA).

17 Jan 2013

Reviews show little evidence of widespread efficacy of mobile health interventions

"Mobile phone technology is frequently heralded as a solution to many health challenges facing the developing world, but two systematic reviews have found that evidence to back such claims is still largely non-existent," SciDev.Net reports.

17 Jan 2013

Tzamal Medical, Duchesnay partner to distribute and sell Diclectin for management of NVP

Duchesnay Inc. and Tzamal Medical Group Ltd today announced that they have signed an agreement whereby Tzamal Medical Group has been granted exclusive rights to distribute and sell throughout the Israeli market the prescription medicine Diclectin (doxylamine 10 mg/pyridoxine 10 mg delayed-release tablet) indicated for the management of nausea and vomiting of pregnancy (NVP).

17 Jan 2013

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013

Speech training holds promise for cochlear implant recipients

Behavioral speech therapy programs are effective and efficient for training speech sound production in adults who have received a cochlear implant, exploratory research findings show.

16 Jan 2013

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.

16 Jan 2013

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

16 Jan 2013

Pfizer’s Quillivant XR now available in the U.S. for treatment of ADHD

Pfizer Inc. today announced that Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD).

16 Jan 2013

Tailored asthma therapy on the horizon

UK researchers report that montelukast therapy is more effective than salmeterol in children with asthma who have a particular genotype – a finding that could pave the way for personalized asthma management.

15 Jan 2013

Pill color switch disrupts medication adherence

Simply changing the appearance of a prescription medication can significantly alter patients’ compliance with treatment, study findings show.

14 Jan 2013

Bionic devices: an interview with Dr Rylie Green

Bionic devices are implants which replace biological functions which have been lost due to nerve damage. They use electrical signals to stimulate the remaining nerve cells following disease or injury. Although the term bionic was only coined in the late 1950s, the earliest bionic devices were cardiac pacemakers, developed in the early 1900s. However the first commercial implantable units were not available until the 1950s.

14 Jan 2013

Additional insights into workings of ALVAC vaccine against HIV

Four years ago, a potential HIV vaccine showed promise against the virus that causes AIDS, but it fell short of providing the broad protection necessary to stem the spread of disease.

11 Jan 2013

Cholera could be contained in Haiti by vaccinating less than half the population

Cholera could be contained in Haiti by vaccinating less than half the population, University of Florida researchers suggest in a paper to be published Thursday in the journal Scientific Reports.

11 Jan 2013

Viewpoints: Rove says GOP unlikely to make much 'structural change' to entitlements; Roe anniversary and fading public understanding; Fast food workers' health insurance

As a matter of policy, rather than politics, it is no more sensible to draw the line at $620 billion in additional revenue over the next decade than to insist, as have some Democrats, that Medicare and Social Security remain untouched. The country's structural deficit poses too large a threat to future prosperity, and there is no politically or fiscally realistic scenario under which entitlement cuts alone can solve the problem.

11 Jan 2013

Parkinson’s assessment devices from Great Lakes NeuroTechnologies receive TGA approval

Great Lakes NeuroTechnologies announced today that they received TGA approval to market Kinesia technology in Australia. The Kinesia™ product line includes patient-worn motion sensors and a tablet computer to quantitatively assess tremor, bradykinesia, and dyskinesia associated with Parkinson’s disease and in response to treatments.

10 Jan 2013

Efficacy News and Research

FDA approves Allergan’s BOTOX to treat overactive bladder

Researchers disagree over ethics of HIV treatment clinical trial in Africa, Nature reports

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

SyNAPSe® Trial by BHR Pharma deemed to have no safety issues according to DSMB

New menu of 61 genetically engineered E. coli strains may improve efficacy of vaccines

QrxPharma to resubmit MOXDUO NDA with FDA

Reviews show little evidence of widespread efficacy of mobile health interventions

Tzamal Medical, Duchesnay partner to distribute and sell Diclectin for management of NVP

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Speech training holds promise for cochlear implant recipients

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Pfizer’s Quillivant XR now available in the U.S. for treatment of ADHD

Tailored asthma therapy on the horizon

Pill color switch disrupts medication adherence

Bionic devices: an interview with Dr Rylie Green

Additional insights into workings of ALVAC vaccine against HIV

Cholera could be contained in Haiti by vaccinating less than half the population

Viewpoints: Rove says GOP unlikely to make much 'structural change' to entitlements; Roe anniversary and fading public understanding; Fast food workers' health insurance

Parkinson’s assessment devices from Great Lakes NeuroTechnologies receive TGA approval

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News